Emcure Pharmaceuticals Limited has informed stock exchanges about a fire incident at its manufacturing facility in Hinjawadi, Pune, Maharashtra on February 07, 2026. The incident occurred at the utility block of Plant I, temporarily disrupting operations at the facility.

Incident Details and Impact

The fire incident took place on February 07, 2026, affecting the utility block of the company's manufacturing plant located at Hinjawadi, Pune. While the fire has been successfully controlled, the cause remains under investigation. The company confirmed that no human injuries or casualties were reported during the incident.

Operational Disruption and Recovery

The fire incident has resulted in temporary disruption of operations at the affected manufacturing plant. The company estimates that operations will remain suspended for a period of 5 to 7 days. Emcure Pharmaceuticals is implementing all necessary measures to restore plant operations at the earliest possible time.

Insurance Coverage and Financial Impact

The company has confirmed that adequate insurance coverage exists for the affected plant. Emcure Pharmaceuticals has already notified the insurance company about the incident and initiated the claims process. According to the company's assessment, the incident is not expected to have a material impact on the company's financial performance, though the full extent of loss and damage is currently being evaluated.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has committed to providing further updates on any developments related to this incident within due time. The communication was signed by Tajuddin Shaikh, Chief Financial Officer of Emcure Pharmaceuticals Limited.

Emcure Pharmaceuticals has announced the re-appointment of three independent directors for their second consecutive terms, following a board meeting held on February 04, 2026. The decision was made based on recommendations from the company's Nomination and Remuneration Committee and is subject to shareholder approval.

Board Approvals and Appointments

The board of directors approved the re-appointment of three key independent directors during the meeting that commenced at 12:40 p.m. (IST) and concluded at 1:15 p.m. (IST). All three directors have been serving the company since April 16, 2021, and are being re-appointed for their second consecutive terms.

Director Profiles and Experience

Dr. Shailesh Kripalu Ayyangar brings over 40 years of experience in healthcare, with deep expertise in pharmaceutical R&D, biologicals, pharmaceutical operations, animal health, and consumer healthcare. He previously served as a member of Sanofi's International Leadership Team and Country Chair for India & South Asia, building the business to become one of the most respected and fast-growing multinational companies in the region. Dr. Ayyangar holds a bachelor's degree in veterinary science and animal husbandry from Gujarat Agricultural University and a post-graduate diploma in management from the Indian Institute of Management, Ahmedabad.

Mr. Vijay Keshav Gokhale holds a master's degree in history and joined the Indian Foreign Service in 1981. His distinguished diplomatic career includes postings in Hong Kong, Hanoi, Beijing, and New York. He served in various senior positions including Secretary (Finance), Director (China & East Asia), High Commissioner to Malaysia (January 2010 to October 2013), Ambassador to Germany (October 2013 to January 2016), Ambassador to China (January 2016 to October 2017), and Foreign Secretary (January 2018 to January 2020).

Dr. Vidya Rajiv Yeravdekar serves as the Principal Director of Symbiosis Society and Pro Chancellor of Symbiosis International University. She has been appointed as a member of the expert group on Global Outreach of Higher Education by UGC to implement the National Education Policy 2020 and serves as a member of the Advisory Group of Analytical and Advisory work (ASA) at the World Bank. Dr. Yeravdekar holds an MBBS degree, a bachelor's degree in law from the University of Pune, and a PhD in internationalization of higher education in India from Symbiosis International University.

Regulatory Compliance

The company confirmed that all three directors are not debarred from holding director positions by SEBI or any other authority, in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018. Additionally, none of the directors are related to any existing directors or key managerial personnel of the company. The appointments comply with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.